LCT is a clinic-ready biotechnology company. We have a compound targeting obesity that will be in clinic in 2021 and a compound targeting migraine that will be in clinic in 2021.
We are also looking to partner to further develop our cell product, NTCELL for Parkinson’s disease.
We are open to discussions with prospective partners for out-licensing, profit-sharing and commercialisation opportunities.
If you are interested in partnering with LCT, please get in touch with CEO, Ken Taylor, firstname.lastname@example.org, +64 9 276 2690.